Idiopathic intracranial hypertension in adolescents with severe visual impairment: Long-term outcome and the beneficial effects of weight loss and psychological support.

Yıl 2012, Cilt: 17 Sayı: 3, 111 - 114, 09.10.2014

Garoufi Anastasia Georgouli Helen Vartzelis George Eliades Andreas Velissariou Joanna Kossiva Lydia

Öz

Abstract. The aim of this manuscript is to evaluate retrospectively, the symptoms, treatment and long-term outcome of idiopathic intracranial hypertension (IIH) in adolescents with severe visual impairment, particularly in relation to body weight and compliance to treatment. We reviewed the clinical notes of adolescent patients treated in our department for IIH through a one-year period. From January 2004 to Feb 2005 four patients, aged between 12 and 13 years were diagnosed with IIH. Inclusion criteria were cerebrospinal fluid (CSF) opening pressure greater than 250 mmH₂O, normal CSF composition, severe visual impairment, normal brain imaging and nonfocal neurological examination except for sixth nerve palsy. All patients were followed for a minimum of 3 years. All patients were either overweight or obese. The sex distribution was 3 girls, 1 boy. The most common presenting symptom was headache. Visual field abnormalities were present in all cases with severe visual loss. All patients were treated with acetazolamide while two of them received steroids in conventional dose and one needed high-dose methylprednisolone. The use of transcranial Doppler (TCD) was available only after treatment with minimum impact on results. Adolescents represent an age group with special emotional and biological needs leading in difficulties when compliance to specific treatment is necessary. Although IIH in adolescents is rare, it could lead in permanent visual loss. Especially in obese patients, successful weight management in combination with good compliance to treatment seems important for a favorable long-term outcome.

Key words: Adolescents, pseudotumor cerebri, treatment, vision, weight loss

Anahtar Kelimeler

Adolescents, pseudotumor cerebri, treatment, vision, weight loss

Kaynakça

• Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59: 1492-1495.
• Baker RS, Carter D, Hendrick EB, Buncic JR. Visual loss in pseudotumor cerebri of childhood. A follow-up study. Arch Ophthalmol 1985; 103: 1681-1686.
• Grant DN. Benign intracranial hypertension. A review of 79 cases in infancy and childhood. Arch Dis Child 1971; 46: 651-655.
• Soler D, Cox T, Bullock P, Calver DM, Robinson RO. Diagnosis and management of benign intracranial hypertension. Arch Dis Child 1998; 78: 89-94.
• Sugerman HJ, DeMaria EJ, Felton WL, 3rd Nakatsuka M, Sismanis A. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology 1997; 49: 507-511.
• Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide:international survey. BMJ 2000; 320: 1-6.
• Gordon K. Pediatric pseudotumor cerebri: descriptive epidemiology. Can J Neurol Sci 1997; 24: 219-221.
• Cinciripini GS, Donahue S. Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. Am J Ophthalmol 1999; 127: 178-182.
• Distelmaier F, Sengler U, Messing-Juenger M, et al. Pseudotumor cerebri as an important differential diagnosis of papilledema in children. Brain Dev 2006; 28: 190-195.
• Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol 2007; 52: 597-617.
• Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R. Opportunities to improve outcomes in sickle cell disease. Am Fam Physician 2006; 74: 303-310.
• Razumovsky AY, Gillard JH, Bryan RN, Hanley DF, Oppenheimer SM. TCD, MRA and MRI in acute cerebral ischemia. Acta Neurol Scand 1999; 99: 65- 76.
• Binder DK, Horton JC, Lawton MT, McDermott MW. Idiopathic intracranial hypertension. Neurosurgery 2004; 54: 538-551.
• Liu GT, Glaser JS, Schatz NJ. High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol 1994; 118: 88-96.